THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechloretamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/A...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1702 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850215661853212672 |
|---|---|
| author | Ercole Brusamolino Manuel Gotti Valeria Fiaccadori |
| author_facet | Ercole Brusamolino Manuel Gotti Valeria Fiaccadori |
| author_sort | Ercole Brusamolino |
| collection | DOAJ |
| description | Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechloretamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/AML). With the introduction of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, this risk has substantially been reduced. In this review, different experiences are discussed to determine whether and how modifications of treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. These data are drawn from large cohorts of patients treated over time with different therapies with an adequate follow-up. |
| format | Article |
| id | doaj-art-8f99a7a710e74173a3f538fbbabd6db3 |
| institution | OA Journals |
| issn | 2035-3006 |
| language | English |
| publishDate | 2014-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-8f99a7a710e74173a3f538fbbabd6db32025-08-20T02:08:34ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPYErcole Brusamolino0Manuel Gotti1Valeria Fiaccadori2Ercole Brusamolino, M.D., Clinica Ematologica, Department of OncoHematology, Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2, Pavia 27100, Italy. Phone: +39-0382-503-074. E-mail: ebrusa@smatteo.pv.itClinica Ematologica, Department of OncoHematology, Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2, Pavia 27100, Italy.Clinica Ematologica, Department of OncoHematology, Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2, Pavia 27100, Italy.Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechloretamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/AML). With the introduction of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, this risk has substantially been reduced. In this review, different experiences are discussed to determine whether and how modifications of treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. These data are drawn from large cohorts of patients treated over time with different therapies with an adequate follow-up.https://mjhid.org/index.php/mjhid/article/view/1702Hodgkin LymphomaTherapy Related Myeloid Neoplasm |
| spellingShingle | Ercole Brusamolino Manuel Gotti Valeria Fiaccadori THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY Mediterranean Journal of Hematology and Infectious Diseases Hodgkin Lymphoma Therapy Related Myeloid Neoplasm |
| title | THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY |
| title_full | THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY |
| title_fullStr | THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY |
| title_full_unstemmed | THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY |
| title_short | THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY |
| title_sort | risk of therapy related myelodysplasia acute myeloid leukemia in hodgkin lymphoma has substantially decreased in the abvd era abolishing mechloretamine and procarbazine and limiting volumes and doses of radiotherapy |
| topic | Hodgkin Lymphoma Therapy Related Myeloid Neoplasm |
| url | https://mjhid.org/index.php/mjhid/article/view/1702 |
| work_keys_str_mv | AT ercolebrusamolino theriskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechloretamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT manuelgotti theriskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechloretamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT valeriafiaccadori theriskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechloretamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT ercolebrusamolino riskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechloretamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT manuelgotti riskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechloretamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT valeriafiaccadori riskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechloretamineandprocarbazineandlimitingvolumesanddosesofradiotherapy |